ADORA3: Adenosine receptor A3
G protein-coupled receptor (GPCR) for adenosine that plays significant roles in various physiological processes including immune regulation, cardioprotection and neuroprotection.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ADORA3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
- Other 1
| Namodenoson | Phase 3 | Can-Fite BioPharma | Small molecule | AgonistAdenosine A3 receptor agonist | 2 |
| Piclidenoson | Phase 3 | Can-Fite BioPharma | Small molecule | AgonistAdenosine A3 receptor agonist | 2 |
| QAF805 | Phase 1 | — | Other | AntagonistAdenosine A3 receptor antagonist | 0 |
| An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome | Piclidenoson | Phase 2 | Not yet recruiting | Can-Fite BioPharma | Feb 13, 2026 |
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy | Piclidenoson | Phase 3 | Not yet recruiting | Can-Fite BioPharma | Oct 16, 2024 |
| Namodenoson Treatment of Advanced Pancreatic Cancer | Namodenoson | Phase 2 | Recruiting | Can-Fite BioPharma | Apr 29, 2024 |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Namodenoson | Phase 3 | Recruiting | Can-Fite BioPharma | Jan 21, 2022 |
- Migraine disorder0.61
- Asthma0.61
- Paroxysmal tachycardia0.59
- Apnea0.57
- Wolff-Parkinson-White syndrome0.56
- Pain0.56
- Airway obstruction0.55
- Headache0.54
- Chronic obstructive pulmonary disease0.49
- Chronic bronchitis0.46
- Paroxysmal supraventricular tachycardia0.43
- Cardiovascular disorder0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL256, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P0DMS8, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets